Merus Labs International Inc (USA)(NASDAQ:MSLI) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during Pre-Market on Feb 14, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $26.069M. Analysts estimated a revenue of $20.960M. The revenues were 24.38% above the estimates. Earnings per share were $-0.05. The reported EPS was below estimates by -150%. Analysts had estimated an EPS of $-0.02.
In a different note, On Dec 15, 2016, CIBC said it Downgrades its rating on Merus Labs International Inc (USA). The shares have been rated ‘Neutral’ by the firm.
Merus Labs International Inc (USA) (MSLI) shares turned negative on Wednesdays trading session with the shares closing down -0.0072 points or -0.83% at a volume of 10,716. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.8599. The peak price level was also seen at $0.8599 while the days lowest was $0.843034. Finally the shares closed at $0.8599. The 52-week high of the shares is $1.76 while the 52-week low is $0.7005. According to the latest information available, the market cap of the company is $101 M.
Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives. Its products include Factive Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.